#United States #Chicago #Brainomix #Pulmonary Fibrosis #Quantitative CT

Early Detection of Progressive Pulmonary Fibrosis Using Quantitative CT

The recent multicenter study led by Brainomix has highlighted the remarkable capabilities of quantitative CT in detecting progressive pulmonary fibrosis (PPF) far earlier than standard clinical methods. The findings, published in The Annals of the American Thoracic Society, suggest that quantitative imaging can provide a critical advantage in managing patients with fibrotic interstitial lung disease (ILD).

Key Findings of the Study

In this significant research involving 509 patients at three prominent US centers, researchers applied Brainomix’s e-Lung quantitative CT tool—an innovative imaging technology recognized by the FDA and CE. The study found that clinicians could detect radiological signs of PPF an average of 16 months prior to traditional clinical diagnoses. In some cases, this detection time stretched to as long as 28 months earlier at one of the centers.

This dramatic lead time can potentially open doors to earlier intervention strategies, allowing physicians to make timely decisions that could greatly enhance patient outcomes. For those patients initially deemed clinically stable, the study identified radiological progression rates that had gone unnoticed, emphasizing the need for advanced imaging in everyday clinical practice.

Implications for Clinical Practice

The ability to objectively quantify changes in lung imaging has significant implications. As current treatments for pulmonary fibrosis primarily aim to slow down disease progression rather than reverse it, utilizing quantitative CT insights could help doctors identify patients at higher risk of severe outcomes sooner. The researchers found that a higher baseline weighted reticulovascular score (WRVS) correlated with an increased risk of future PPF, while a small alteration in disease extent noted on follow-up scans was linked to heightened mortality risk.

Dr. Ayodeji Adegunsoye, a pulmonary specialist at the University of Chicago Medicine and lead author of the study, stressed the value of integrating these quantitative insights into clinical workflows. By recognizing disease progression sooner, clinicians can make more informed treatment decisions and better monitor patients’ conditions.

Statement from Industry Leaders

According to Professor Peter George, principal investigator and Consultant Pulmonologist at Royal Brompton Hospital, the subtle changes detectable by quantitative CT represent a crucial edge over conventional assessment methods which might not pick up on early disease changes. These findings underscore the need to incorporate objective imaging metrics into routine ILD care as they could significantly improve the management of pulmonary fibrosis and potentially preserve lung function before significant deterioration occurs.

Industry support for this research was provided by leading biopharmaceutical company Boehringer Ingelheim, which is committed to advancing therapeutic options for ILD patients. Martin Beck, Senior Vice President at Boehringer, emphasized the urgency for prompt identification of disease progression in conditions such as PPF, where irreversible loss of lung function can occur.

Future Directions

Building on the insights from the REVISE-PPF study, Brainomix plans to continue their partnership with Boehringer Ingelheim through the upcoming PROGRESS-PPF study. This prospective investigation will further examine how AI-driven quantitative outputs from tools like e-Lung can enhance clinicians’ understanding of PPF, ultimately aiming for a more proactive and preventative healthcare approach.

The study serves as a vital stepping stone in the evolution of pulmonary fibrosis management, potentially leading to improved protocols that are more responsive to the evolving landscape of this challenging disease. For more detailed information about Brainomix and its pioneering work in medical imaging, visit www.brainomix.com.